Skip to main content

Table 2 The cumulative annual cost saving, cost - effectiveness and cost – benefit of SIF in Montreal using the Jacobs et al.[18] model

From: A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada

Variables

Annual cost of operation

Sharing rate

# of HIV averted

# of HCV averted

HIV cost saved

HCV cost saved

Cost-effectiveness ratio HCV

Cost-effectiveness ratio HIV

Cost-benefit ratio HCV

Cost-benefit ratio HIV

Post SIF

$2,182,800

35%

14

84

$764,970

$769,212

$25,986

$155,914

1.35

1.35

Two SIF

$4,365,600

28%

26

162

$1,108,830

$1,327,566

$26,948

$167,908

1.25

1.25

Three SIF

$6,548,400

21%

32

195

$189,360

$304,485

$33,582

$204,637

1.03

1.03

Four SIF

$8,731,200

18%

37

227

-$940,665

-$753,739

$38,463

$235,978

0.89

0.89

Five SIF

$10,914,000

16%

43

261

-$1,860,135

-$1,741,677

$41,816

$253,814

0.83

0.83

Six SIF

$13,096,800

13%

48

294

-$2,990,160

-$2,764,758

$44,547

$272,850

0.77

0.77

Seven SIF

$15,279,600

10%

53

327

-$4,120,185

-$3,787,839

$46,727

$288,294

0.73

0.73

Average

$8,731,200

7%

36

221

-$1,151,220

-$964,597

$39,508

$242,533

0.87

0.87